| Systemic Treatment for Patients with Early-Stage Breast Cancer |
|
Hee Kyung Ahn |
|
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea |
| 조기 유방암의 전신 치료 |
|
안희경 |
|
성균관대학교 의과대학 삼성서울병원 혈액종양내과 |
Correspondence:
Hee Kyung Ahn, Tel: +82-2-3410-1794, Email: hkahn.onco@gmail.com
|
|
Received: 7 January 2026 • Revised: 2 March 2026 • Accepted: 10 March 2026 |
|
|
| Abstract |
|
Breast cancer is the most common malignancy among women in Korea and its incidence is rapidly increasing. Perioperative systemic treatment plays a critical role in achieving a cure for early-stage breast cancer. With the introduction of novel systemic agents, treatment outcomes have improved and perioperative strategies have become increasingly diverse. In addition to conventional anthracycline- and taxane-based chemotherapies, targeted therapies and/or immunotherapy have expanded the options to both neoadjuvant and adjuvant settings. Increasing numbers of (neo) novel adjuvant agents and post-neoadjuvant treatments have demonstrated survival benefits, supporting more individualized perioperative treatment approaches in patients with early breast cancer. |
| Key Words:
Breast neoplasms; Adjuvant chemotherapy; Immunotherapy; Neoadjuvant therapy |
| 주제어:
유방암; 보 조 항암 화학 요법; 면역관문억제제; 선행 요법 |
PDF Links
Full text via DOI
Download Citation
